Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,104,145 articles, preprints and more)

Search results

1-25 of 124 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

Augmenting CAR T-cell Functions with LIGHT.
Cai W, Tanaka K, Mi X, Rajasekhar VK, Khan JF, Yoo S, de Stanchina E, Rahman J, Mathew S, Abrahimi P, Souness S, Purdon TJ, McDowell JR, Meyerberg J, Fujino T, Healey JH, Abdel-Wahab O, Scheinberg DA, Brentjens RJ, Daniyan AF
Cancer Immunol Res, 12(10):1361-1379, 01 Oct 2024
Cited by: 0 articles | PMID: 38959337
Add to export list
TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models.
Hackett CS, Hirschhorn D, Tang MS, Purdon TJ, Marouf Y, Piersigilli A, Agaram NP, Liu C, Schad SE, de Stanchina E, Rafiq S, Monette S, Wolchok JD, Merghoub T, Brentjens RJ
Mol Ther Oncol, 32(3):200862, 22 Aug 2024
Cited by: 0 articles | PMID: 39308793 | PMCID: PMC11415964
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Author Correction: T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection.
Stephan MT, Ponomarev V, Brentjens RJ, Chang AH, Dobrenkov KV, Heller G, Sadelain M
Nat Med, 30(6):1788, 01 Jun 2024
Cited by: 0 articles | PMID: 38418853
Add to export list
Developing a membrane-proximal CD33-targeting CAR T cell.
Freeman R, Shahid S, Khan AG, Mathew SC, Souness S, Burns ER, Um JS, Tanaka K, Cai W, Yoo S, Dunbar A, Park Y, McAvoy D, Hosszu KK, Levine RL, Boelens JJ, Lorenz IC, Brentjens RJ, Daniyan AF
J Immunother Cancer, 12(5):e009013, 20 May 2024
Cited by: 0 articles | PMID: 38772686 | PMCID: PMC11110598
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Author Correction: Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.
Zakrzewski JL, Suh D, Markley JC, Smith OM, King C, Goldberg GL, Jenq R, Holland AM, Grubin J, Cabrera-Perez J, Brentjens RJ, Lu SX, Rizzuto G, Sant'Angelo DB, Riviere I, Sadelain M, Heller G, Zúñiga-Pflücker JC, Lu C, van den Brink MRM
Nat Biotechnol, 42(4):674, 01 Apr 2024
Cited by: 0 articles | PMID: 38531977
Add to export list
Endogenous CD28 drives CAR T cell responses in multiple myeloma
Lieberman MM, Tong JH, Odukwe NU, Chavel CA, Purdon TJ, Burchett R, Gillard BM, Brackett CM, McGray AJR, Bramson JL, Brentjens RJ, Lee KP, Olejniczak SH
bioRxiv, 24 Mar 2024
Cited by: 0 articles | PPR: PPR826612
Add to export list Preprint
Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.
Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, Schluter J, Fontana E, Taur Y, Park JH, [...] Ruella M
Nat Med, 29(11):2954, 01 Nov 2023
Cited by: 3 articles | PMID: 36253610 | PMCID: PMC11270898
Add to export list Free full text in Europe PMC
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.
Park JH, Nath K, Devlin SM, Sauter CS, Palomba ML, Shah G, Dahi P, Lin RJ, Scordo M, Perales MA, Shouval R, Tomas AA, Cathcart E, Mead E, Santomasso B, Holodny A, Brentjens RJ, Riviere I, Sadelain M
Nat Med, 29(7):1710-1717, 03 Jul 2023
Cited by: 29 articles | PMID: 37400640 | PMCID: PMC11462637
Add to export list Free full text in Europe PMC
IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models.
Jaspers JE, Khan JF, Godfrey WD, Lopez AV, Ciampricotti M, Rudin CM, Brentjens RJ
J Clin Invest, 133(9):e166028, 01 May 2023
Cited by: 36 articles | PMID: 36951942 | PMCID: PMC10145930
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
CAR T cell therapy: looking back and looking forward.
Davila ML, Brentjens RJ
Nat Cancer, 3(12):1418-1419, 01 Dec 2022
Cited by: 6 articles | PMID: 36539498
Add to export list
GPRC5D-Targeted CAR T Cells for Myeloma. Reply.
Mailankody S, Brentjens RJ, Smith EL
N Engl J Med, 387(24):2296, 01 Dec 2022
Cited by: 3 articles | PMID: 36516098
Add to export list
GPRC5D-Targeted CAR T Cells for Myeloma.
Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, Russo D, Auclair R, Fitzgerald L, Cadzin B, Wang X, Sikder D, Senechal B, Bermudez VP, Purdon TJ, Hosszu K, McAvoy DP, Farzana T, Mead E, [...] Smith EL
N Engl J Med, 387(13):1196-1206, 01 Sep 2022
Cited by: 131 articles | PMID: 36170501 | PMCID: PMC10309537
Add to export list Free full text in Europe PMC
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion.
Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, Sauter CS, Shah NN, Abou-El-Enein M
Nat Rev Clin Oncol, 19(5):342-355, 22 Mar 2022
Cited by: 104 articles | PMID: 35318469
Add to export list Review
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.
Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, Schluter J, Fontana E, Taur Y, Park JH, [...] Ruella M
Nat Med, 28(4):713-723, 14 Mar 2022
Cited by: 107 articles | PMID: 35288695 | PMCID: PMC9434490
Add to export list Free full text in Europe PMC
CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience.
Palomba ML, Qualls D, Monette S, Sethi S, Dogan A, Roshal M, Senechal B, Wang X, Rivière I, Sadelain M, Brentjens RJ, Park JH, Smith EL
J Immunother Cancer, 10(2):e004128, 01 Feb 2022
Cited by: 11 articles | PMID: 35173030 | PMCID: PMC8852764
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Multipurposing CARs: Same engine, different vehicles.
Hossian AKMN, Hackett CS, Brentjens RJ, Rafiq S
Mol Ther, 30(4):1381-1395, 11 Feb 2022
Cited by: 9 articles | PMID: 35151842 | PMCID: PMC9077369
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Engineering CAR-T cells to activate small-molecule drugs in situ.
Gardner TJ, Lee JP, Bourne CM, Wijewarnasuriya D, Kinarivala N, Kurtz KG, Corless BC, Dacek MM, Chang AY, Mo G, Nguyen KM, Brentjens RJ, Tan DS, Scheinberg DA
Nat Chem Biol, 18(2):216-225, 30 Dec 2021
Cited by: 28 articles | PMID: 34969970 | PMCID: PMC9152922
Add to export list Free full text in Europe PMC
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells.
Pennisi M, Sanchez-Escamilla M, Flynn JR, Shouval R, Alarcon Tomas A, Silverberg ML, Batlevi C, Brentjens RJ, Dahi PB, Devlin SM, Diamonte C, Giralt S, Halton EF, Jain T, Maloy M, Mead E, Palomba ML, Ruiz J, Santomasso B, [...] Perales MA
Blood Adv, 5(17):3397-3406, 01 Sep 2021
Cited by: 64 articles | PMID: 34432870 | PMCID: PMC8525234
Add to export list Free full text in Europe PMC
Human cytomegalovirus expands a CD8⁺ T cell population with loss of BCL11B expression and gain of NK cell identity.
Sottile R, Panjwani MK, Lau CM, Daniyan AF, Tanaka K, Barker JN, Brentjens RJ, Sun JC, Le Luduec JB, Hsu KC
Sci Immunol, 6(63):eabe6968, 24 Sep 2021
Cited by: 25 articles | PMID: 34559552 | PMCID: PMC8601152
Add to export list Free full text in Europe PMC
Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy.
Wudhikarn K, Flynn JR, Rivière I, Gönen M, Wang X, Senechal B, Curran KJ, Roshal M, Maslak PG, Geyer MB, Halton EF, Diamonte C, Davila ML, Sadelain M, Brentjens RJ, Park JH
Blood, 138(7):531-543, 01 Aug 2021
Cited by: 41 articles | PMID: 33851211 | PMCID: PMC8377478
Add to export list Free full text in Europe PMC
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab.
Adusumilli PS, Zauderer MG, Rivière I, Solomon SB, Rusch VW, O'Cearbhaill RE, Zhu A, Cheema W, Chintala NK, Halton E, Pineda J, Perez-Johnston R, Tan KS, Daly B, Araujo Filho JA, Ngai D, McGee E, Vincent A, Diamonte C, [...] Sadelain M
Cancer Discov, 11(11):2748-2763, 15 Jul 2021
Cited by: 221 articles | PMID: 34266984 | PMCID: PMC8563385
Add to export list Free full text in Europe PMC
Depletion of high-content CD14⁺ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing.
Wang X, Borquez-Ojeda O, Stefanski J, Du F, Qu J, Chaudhari J, Thummar K, Zhu M, Shen LB, Hall M, Gautam P, Wang Y, Sénéchal B, Sikder D, Adusumilli PS, Brentjens RJ, Curran K, Geyer MB, Mailankhody S, [...] Rivière I
Mol Ther Methods Clin Dev, 22:377-387, 16 Jul 2021
Cited by: 20 articles | PMID: 34514029 | PMCID: PMC8411225
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Chimeric Antigen Receptor-Modified Immune Effector Cell Therapies: Learning From the Present; Charting a Path to the Future.
Smith EL, Brentjens RJ
Cancer J, 27(2):90-91, 01 Mar 2021
Cited by: 0 articles | PMID: 33750066 | PMCID: PMC8285986
Add to export list Free full text in Europe PMC
Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition.
Yeku OO, Rao TD, Laster I, Kononenko A, Purdon TJ, Wang P, Cui Z, Liu H, Brentjens RJ, Spriggs D
Front Immunol, 12:663379, 14 Apr 2021
Cited by: 17 articles | PMID: 33936101 | PMCID: PMC8079980
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia.
Perica K, Flynn J, Curran KJ, Rivere I, Wang X, Senechal B, Halton E, Diamonte C, Pineda J, Bernal Y, Gonen M, Sadelain M, Brentjens RJ, Park JH
Leukemia, 35(11):3268-3271, 08 Mar 2021
Cited by: 16 articles | PMID: 33686196 | PMCID: PMC8423852
Add to export list Free full text in Europe PMC

1-25 of 124 results

1 2 3 Next ...

Search life-sciences literature (45,104,145 articles, preprints and more)

Search results

Augmenting CAR T-cell Functions with LIGHT.

TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models.

Author Correction: T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection.

Developing a membrane-proximal CD33-targeting CAR T cell.

Author Correction: Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.

Endogenous CD28 drives CAR T cell responses in multiple myeloma

Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.

CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.

IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models.

CAR T cell therapy: looking back and looking forward.

GPRC5D-Targeted CAR T Cells for Myeloma. Reply.

GPRC5D-Targeted CAR T Cells for Myeloma.

Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion.

Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.

CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience.

Multipurposing CARs: Same engine, different vehicles.

Engineering CAR-T cells to activate small-molecule drugs in situ.

Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells.

Human cytomegalovirus expands a CD8⁺ T cell population with loss of BCL11B expression and gain of NK cell identity.

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy.

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab.

Depletion of high-content CD14⁺ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing.

Chimeric Antigen Receptor-Modified Immune Effector Cell Therapies: Learning From the Present; Charting a Path to the Future.

Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition.

Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia.

Partnerships & funding